Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olaparib Maintenance Therapy in Patients With Metastatic Breast Cancer Following DNA-damaging Based Chemotherapy

NCT05629429 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05629429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olaparib Maintenance Therapy in Patients With Metastatic Breast Cancer Following DNA-damaging Based Chemotherapy
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 7, 2023
Completion date
December 31, 2025
Enrollment
300 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer